Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)

Clinical Trial Details

The purpose of this study is to test the oral drug KRT-232 for the treatment of acute myeloid leukemia (AML).  This study will determine if this drug is able to reduce the growth of unhealthy or tumor cells and help restore the function of the bone marrow.

KRT-232 is considered investigational, meaning that it has not yet been approved by the U.S. Food and Drug Administration (FDA) for the treatment of AML.

The study drug will be given to you either alone or along with another therapy for AML assigned by the study doctor. The other therapy will be either cytarabine (injected under the skin) or decitabine (injected into a vein). Discussions about the assigned drugs and doses will take place between participants and the study doctor prior to beginning the trial.

Regardless of which drug or drug combinations participants are assigned, each cycle will be 28 days long and participants will come into the office for weekly outpatient visits.

Key Eligibility: 
  1. Over the age of 18
  2. Patients may have been treated with more than 1 prior line of therapy for AML secondary to MPN. 

Detailed eligibility will be reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan

Contact(s)

Tania J. Curcio, NP, FNP-BC
(212) 746-2571
tjc9003@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2004021834

ClinicalTrials.gov:

NCT04113616

Sponsor:

KRT-232-104

Status

Open to Enrollment

Age Group

Adult

Sponsor